G0S2 and coronary artery disorder: The expression of G0S2, an inhibitor of ATGL, was increased at the mRNA level in CAD patients (+50.5%, p < 0.05, Figure 2C), however, there were no significant alterations in its protein content (+22.7%, p < 0.05, Figure 1C).